Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Virk, Selene M ^a   Gibson, Richard M ^b   Quinones Mateu, Miguel E ^a,b,c   Barnholtz Sloan, Jill S ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN; PROTEIN PATCHED 1; CELL SURFACE RECEPTOR; PROTEIN PATCHED; PTCH PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPREHENSIVE CANCER PANEL; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENE TECHNOLOGY; GENETIC ANALYZER; GENETIC PROCEDURES; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NF1 GENE; PILOT STUDY; PRIMARY TUMOR; PTCH1 GENE; SEQUENCE ANALYSIS; WHOLE EXOME SEQUENCING; BRAIN TUMOR; DNA SEQUENCE; EXOME; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PROCEDURES;

ADULT; BRAIN NEOPLASMS; EXOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GLIOBLASTOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMIN 1; PATCHED RECEPTORS; PATCHED-1 RECEPTOR; PILOT PROJECTS; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, DNA;

EID: 84929079763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124178     Document Type: Article

References (25)

1. Ostrom QT, Gittleman H, Lao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014 Oct; 16 Suppl 4:iv1-63. doi: 10.1093/neuonc/nou223 PMID: 25304271
2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society. 2014. Available: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J of Med. 2005; 10: 987-996. doi: 10.1056/NEJMoa043330
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J of Med. 2008; 359: 492-507. doi: 10.1056/NEJMra0708126
5. Riehmer V, Gietzelt J, Beyer U, Hentschel B, Westphal M, Shackert G, et al. Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. Genes Chromosomes Cancer. 2014; 53: 589-605. doi: 10.1002/gcc.22169 PMID: 24706357
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812. doi: 10.1126/science.1164382 PMID: 18772396
7. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068. doi: 10.1038/nature07385
8. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013; 110: 4009-4014. doi: 10.1073/pnas.1219747110 PMID: 23412337
9. Nickel GC, Barnholtz-Sloan J, Gould MP, McMahon S, Cohen A, Adams MD, et al. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS ONE. 2013; 7: e35262. doi: 10.1371/journal.pone.0035262
10. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173. doi: 10.1016/j.ccr.2006.02.019 PMID: 16530701
11. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110. doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251
12. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501. doi: 10.1038/nature12912 PMID: 24390350
13. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45: 1127-1133. doi: 10.1038/ng.2762 PMID: 24071851
14. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339. doi: 10.1038/nature12634 PMID: 24132290
15. Liu L, Li Y, Li S, Hu N, He Y, Pong R, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012; 2012: 251364. doi: 10.1155/2012/251364 PMID: 22829749
16. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011; 475: 348-352. doi: 10.1038/nature10242 PMID: 21776081
17. Gibson RM, Schmotzer CL, Quinones-Mateu ME. Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use? Curr Infect Dis Rep. 2014; 16:401. doi: 10.1007/s11908-014-0401-5 PMID: 24585216
18. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155: 462-477. doi: 10.1016/j.cell.2013.09.034 PMID: 24120142
19. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Gabriel S, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31: 213-219. doi: 10.1038/nbt.2514 PMID: 23396013
20. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011; 3: 111ra121. doi: 10.1126/scitranslmed.3003161 PMID: 22133722
21. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011; 32: 177-195. PMID: 22147957
22. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31: 1023-1031. doi: 10.1038/nbt.2696 PMID: 24142049
23. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-105. doi: 10.1038/nature11284 PMID: 22832583
24. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn. 2013; 15: 171-176. doi: 10.1016/j.jmoldx.2012.09.003 PMID: 23274167
25. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, et al. Clinical validation of a nextgeneration sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15: 607-622. doi: 10.1016/j.jmoldx.2013.05.003 PMID: 23810757